价格

FUJI YAKUHIN CO., LTD.

ACTIVE

2-14-25, MIZUMOTO, Katsushika-Ku, Tokyo, 日本www.fujiyakuhin.co.jpPrivate10,001+ 名员工成立于: 1930-02-01

概览

试验阶段分布

阶段

试验数

占比

2 期

44.0%

3 期

20.0%

1 期

16.0%

不适用

4.0%

Unknown

4.0%

试验状态分布

进行中（未招募）

8.0%

已完成

60.0%

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

近期批准

资讯

Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development

- Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report. - Leading companies in hyperuricemia drug development include LG Chem, Shanton Pharma, InventisBio, Jiangsu HengRui Medicine, and Selecta Biosciences, with treatments spanning oral, intravenous, and subcutaneous administration routes. - A significant development occurred in December 2024 when Atom Therapeutics partnered with China Medical System Holdings to commercialize lingdolinurad (ABP-671), a novel URAT1 inhibitor for chronic gout and hyperuricemia in China.

May 8, 2025

返回机构列表

FUJI YAKUHIN CO., LTD.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（25）

A Phase III Study of FYU-981 in Hyperuricemic Pediatric Patients with or without Gout (Extension Study)

A Phase II Study of FYU-981 in Hyperuricemic Pediatric Patients with or without Gout

Study of FFI-1010 in Pediatric Kidney Disease

INULEAD Injection PMS

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Study of FYU-981 in Hyperuricemia With or Without Gout

Mass Balance Study of FYU-981

Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)

药物批准

按机构分类的批准

近期批准

资讯

Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development